Today's sector market value: $9.82B +8.98%
The sector has rebounded strongly and is closely linked to the broader market, with innovative achievements gradually being realized.
📈 Top 10 Coingecko Trading Volume in 24h:
Token Trading Volume Market Cap Price Volatility
1- $VIRTUAL $274.1M $1.1B $1.62 +14.5%
2- $SAHARA $168.0M $164.0M $0.08 -2.7%
3- $KAITO $133.1M $392.5M $1.63 +2.7%
4- $TAO $131.5M $3.0B $335.21 +5.3%
5- $AI16Z $74.0M $179.1M $0.16 +18.1%
6- $BANANAS31 $67.3M $136.7M $0.01 +2.5%
7- $AIXBT $62.8M $127.7M $0.13 +11.2%
8- $PROMPT $53.0M $31.7M $0.14 +10.7%
9- $GOAT $38.9M $110.3M $0.11 +20.2%
10- $TUT $25.0M $49.1M $0.06 -3.8%
⭐️ Key Information
- Mira @Mira_Network explained how to enhance the reliability of AI outputs through a 'consensus mechanism.' First, it breaks down complex outputs into smaller, verifiable statements, each independently verified by a distributed network. Then, multiple models participate in verification, and the results are only recognized when all participants reach consensus. Additionally, models participating in verification must stake tokens and perform real AI inference, combining Proof of Work and Proof of Stake to ensure the fairness and credibility of the verification process.
Comment: Mira has achieved the goal of eliminating AI illusions through the clever design of a 'consensus mechanism' among models.
- Bittensor Subnet No. 68 @metanova_labs has released its operational data since going live: it completed the screening of 4.6 million molecules in 4 months, covering 7,000 protein targets and exploring a chemical library of over 1 billion compounds, making it one of the largest and most efficient decentralized drug screening practices known to date.
METANOVA LABS is a biotechnology company based on cryptographic technology. Relying on the Bittensor network, its decentralized drug screening subnet utilizes the $NOVA token incentive mechanism to integrate global computing resources and the collective wisdom of participants, achieving a drug screening process without upfront computational costs.
Comment: The immense potential of AI in the biopharmaceutical field has been confirmed, and NOVA has realized decentralized AI drug screening through Bittensor, representing both progress in AI drug development and enriching the application landscape of the Bittensor ecosystem.
- ASIMOV @ASIMOV_Protocol released the first phase product of ASIMOV, a multilingual development platform focused on trusted neural-symbolic AI. Neural-symbolic AI combines the advantages of neural networks and symbolic AI while providing cryptographic proofs to ensure that the source of information is clear and trustworthy. The platform supports converting any URL into a knowledge graph usable by large language models and features a fully modular design, allowing users to develop ASIMOV modules to access and utilize various specific data sources.
Comment: We previously mentioned that knowledge graphs can enhance the accuracy of AI outputs, and the launch of the ASIMOV platform further advances this by freeing AI from the 'black box' model, making the training and inference processes of models more transparent, understandable, and auditable.
📊 Data Source: @xhunt_ai, Cookie DAO, Coingecko
💡 Risk Warning: The above is for information sharing only and is not investment advice.